A 6-month Study to Evaluate Sulforaphane Effects in PD Patients
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Parkinson's disease (PD) is a second common neurodegenerative disease. More than 6 million
individuals worldwide have Parkinson disease. No disease-modifying pharmacologic treatments
are available. Current medical treatment is symptomatic, focused on improvement in motor (eg,
tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs
and symptoms. Accumulating evidence suggests the important role for inflammation and
oxidative stress in the pathogenesis of PD. Sulforaphane extracted from broccoli sprout is an
agent with potent anti-oxidant and anti-inflammatory activity. Previous studies suggested
sulforaphane is useful in dopaminergic neuron survival. In this study, the investigator
attempts to evaluate the efficacy and safety of sulforaphane in PD patients.